A company focused on the research and development of medical imaging AI diagnosis has made breakthroughs in the development of intelligent detection systems for pulmonary nodules, but faces problems such as scattered patent layouts and a disconnect between academic achievements and clinical needs. The system achieves a lung nodule detection rate of 98.5% and a false positive rate of 1.2% through deep learning algorithms, but the research and development team has only applied for 2 software copyrights and has not formed a system patent protection; Simultaneously published papers focus on algorithm optimization details and do not highlight clinical application value, making it difficult to gain hospital recognition.

We conducted in-depth technology exploration in our enterprise R&D center and partner hospitals. Through in-depth interviews with algorithm engineers and radiologists, we identified 15 technological innovations, including image preprocessing algorithms, feature extraction models, and clinical decision support. In response to the issue of patent layout, a three-layer patent layout strategy of "core algorithm+application scenario+hardware adaptation" has been developed to assist enterprises in completing 22 patent applications. Among them, 16 invention patents form a full chain protection from algorithm research and development to clinical application, especially the patent of "a method for distinguishing benign and malignant pulmonary nodules based on multimodal fusion", which solves the problem of misdiagnosis in the industry.

In terms of academic paper improvement, the R&D team was guided to write 6 academic papers based on clinical needs, focusing on topics such as "Clinical efficacy evaluation of AI assisted diagnostic systems" and "Adaptive optimization of data in different medical institutions". Among them, 3 papers were included in the Chinese Journal of Radiology, and 2 papers were presented at the International Conference on Medical Imaging Computing and Computer Aided Intervention (MICCAI). The papers cited authorized patents of the enterprise as technical support, enhancing the clinical practicality of the research. At the same time, assist enterprises in incorporating two core patented technologies into the "Clinical Application Guidelines for Medical AI Products" and develop proposals to promote technical indicators as industry recommended standards.

After one year of project implementation, the number of enterprise patents increased tenfold, forming an effective technical barrier and successfully preventing low-priced competition among competitors. The coverage rate of products in tertiary hospitals increased from 15% to 40%. Academic papers have been cited 230 times, and companies have been invited to participate in the development of three national medical AI standards. The technology premium capability has significantly improved, and the unit price of system products has increased by 25%. The annual sales revenue has exceeded 150 million yuan, making it a technological benchmark in the field of medical imaging AI.